VPT:CC - Ventripoint Expands Advisory Board with addition of Ultrasound AI Executive
(TheNewswire)
Toronto, Ontario – TheNewswire - April 30, 2025 – VentripointDiagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) has increasedthe depth of its commercial experience with the addition of StuartGall to the company's Business Advisory Board to provide advice andguidance on the commercialization of Ventripoint’s AI-powered,heart-scanning technology by hospitals and clinics around the world.
With its proprietary VMS+™ platform, Ventripoint is revolutionizingcardiac diagnostics by delivering a powerful AI-driven solution thatenhances echocardiography and serves as an affordable and moreaccessible alternative to traditional MRI scans. Following recentregulatory milestones, Ventripoint is now primed to expand itspresence in key markets and drive widespread adoption
A seasoned health technology executive, Stuart is ChiefExecutive Officer of Intelligent Ultrasound
(AIM: MED), a company that develops artificial intelligence-basedclinical image analysis software tools for the diagnostic medicalultrasound market and hi-fidelity simulators for the ultrasoundtraining market. Based in the UK and US, Intelligent Ultrasound hasa portfolio of market leading products used in approximately 500medical institutions around the world. Previously, Stuart was
a joint founder and executive director of Fusion IP plc, an AIM listedIP commercialisation company, that was acquired for £103 million.Stuart has over 25 years’ experience in both small company start-upsand public companies and previously worked at British Airways plc, ThePromotions Partnership Limited, Anvil Limited and Toad plc (now 21stCentury Technology plc).
“Stuart has demonstrated the ability to repeatedly build successfultechnology ventures” said Ventripoint’s CEO Hugh MacNaught.“With VMS+™ 4.0 being cleared for sale in multiple marketsStuart’s insights and experience and will be extremely helpful inadvancing Ventripoint toward commercial success.”
Added Gall: “Ventripoint's VMS+™ offers an AI enhancement toechocardiography that provides a fast, inexpensive and accessiblealternative to MRIs. This product enables active cardiology practicesto provide more timely management of the needs of patients withcomplex and challenging conditions.”
For further information, pleasecontact:
Hugh MacNaught
(604) 671-4201
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
About Ventripoint DiagnosticsLtd.
Ventripoint has become an industry leader in the application of AI(Artificial Intelligence) to echocardiography. Ventripoint's VMSproducts are powered by its proprietary KBR technology, which is theresult of a decade of development and provides accurate volumetriccardiac measurements equivalent to MRI. This affordable, gold-standardalternative allows cardiologists greater confidence in the managementof their patients. Providing better care to patients serves as aspringboard and basic standard for all Ventripoint's products thatguide our future developments. In addition, VMS+ is versatile and canbe used with all ultrasound systems from any vendor supported byregulatory market approvals in the U.S., Europe and Canada.
Forward Looking Statements
This news release contains forward-looking statements andforward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and information address future eventsand conditions, by their very nature they involve inherent risks anduncertainties. Actual results could differ materially from thosecurrently anticipated due to several factors and risks. Factors whichcould materially affect such forward-looking information are describedin the risk factors in the Company's most recent annual management'sdiscussion and analysis that is available on the Company's profile onSEDAR at www.sedar.com. Readers are cautioned that theforegoing list of factors is not exhaustive. The forward-lookingstatements included in this news release are expressly qualified bythis cautionary statement. The forward-looking statements andinformation contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether becauseof new information, future events or otherwise, unless so required byapplicable securities laws.
Copyright (c) 2025 TheNewswire - All rights reserved.